3M Drug Delivery Systems has a proven track record in pharmaceutical product development and world-class global manufacturing facilities for inhaled, transdermal, oral and topical dosage forms. From early feasibility studies and initial product development to clinical supplies and scale-up for commercial manufacturing, our partners benefit from our robust processes and streamlined operations.
As speed to market is vital, 3M’s track record of single cycle reviews is a particular benefit. Early collaboration between R&D and manufacturing helps ensure that what works at laboratory-scale levels can be translated into manufacturing processes and a regulatory package that is comprehensive and aligned to regulatory expectations.
3M has a long history of leading the industry in innovation. In 1956, our scientists produced the world’s first pressurised metered-dose inhaler (MDI). In 1995, 3M became an environmental pioneer by creating the first chlorofluorocarbon (CFC)-free MDI, replacing CFC with hydrofluoralkane. Today, 3M continues to be a leader in innovation, exploring next-generation drug delivery and alternative propellants that have a lower environmental impact.
